{"id":787658,"date":"2026-01-29T17:17:02","date_gmt":"2026-01-29T17:17:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=787658"},"modified":"2026-01-29T17:17:02","modified_gmt":"2026-01-29T17:17:02","slug":"endra-life-sciences-nasdaq-ndra-gaining-attention-as-hype-token-surges-see-why-now-feed-ser-trx-xhld-batl-inside","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/endra-life-sciences-nasdaq-ndra-gaining-attention-as-hype-token-surges-see-why-now-feed-ser-trx-xhld-batl-inside_787658.html","title":{"rendered":"ENDRA Life Sciences (NASDAQ: NDRA) Gaining Attention as HYPE Token Surges See Why Now! FEED, SER, TRX, XHLD, BATL Inside"},"content":{"rendered":"
\"ENDRA<\/a><\/div>\n

As markets increasingly blur the line between traditional finance and digital assets, ENDRA Life Sciences (NASDAQ: NDRA)<\/strong> is emerging as a unique small-cap story positioned at the intersection of health-tech innovation and next-generation treasury strategy<\/strong>. Recent developments in the digital asset markets—particularly the sharp rise in the HYPE token<\/strong>—are drawing renewed attention to companies that have strategically aligned their balance sheets with this convergence.<\/p>\n

HYPE Token Momentum Signals a Broader Market Shift<\/strong><\/p>\n

The HYPE token<\/strong>, associated with the rapidly expanding Hyperliquid<\/strong> ecosystem, has surged more than 50% in recent trading<\/strong>, significantly outperforming bitcoin, ether, and broader market indices such as the CoinDesk 20. The rally has been attributed to accelerating trading activity and Hyperliquid’s expansion beyond crypto derivatives into tokenized trading of equity indices, individual stocks, commodities, and major fiat pairs<\/strong>.<\/p>\n

Market observers describe this move as a clear signal of crypto–traditional market convergence<\/strong>—a theme gaining traction as decentralized platforms increasingly mirror instruments long associated with Wall Street. According to commentary cited by CoinDesk<\/strong>, this evolution reflects how digital markets are no longer operating in opposition to traditional finance, but increasingly alongside it. See Hyperliquid’s HYPE surges 50% as crypto and traditional worlds merge<\/a>.<\/p>\n

How This Connects to ENDRA Life Sciences<\/strong><\/p>\n

ENDRA is not a crypto company<\/strong>, and its core business remains firmly rooted in healthcare. The Company is the developer of TAEUS® (Thermo-Acoustic Enhanced UltraSound)<\/strong>, a breakthrough imaging platform designed to provide real-time, non-invasive liver fat measurement at the point of care<\/strong>. TAEUS® targets steatotic liver disease (SLD)<\/strong> and MASH<\/strong>, conditions affecting more than two billion people globally<\/strong> and representing one of the largest unmet needs in modern medicine—particularly as GLP-1 therapies<\/strong> drive demand for frequent liver monitoring.<\/p>\n

However, ENDRA has also taken a forward-looking approach to capital efficiency<\/strong> by implementing a Next-Generation Treasury strategy<\/strong> managed by Arca Investment Management. As part of this strategy, ENDRA has disclosed exposure to HYPE<\/strong> within its treasury framework—positioning the company to benefit from upside in digital-asset-driven financial infrastructure without changing its core healthcare mission<\/strong>.<\/p>\n

Why the Timing Matters for Investors<\/strong><\/p>\n

The recent 50% surge in HYPE<\/strong> underscores growing institutional interest in platforms that bridge traditional and digital markets. For ENDRA, this creates a dual-engine investment thesis<\/strong>:<\/p>\n

    \n
  1. Clinical Upside:<\/strong>\n